Capivasertib + Fulvestrant injection
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
Conditions
CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
Trial Timeline
Dec 4, 2024 → Aug 31, 2026
NCT ID
NCT06607757About Capivasertib + Fulvestrant injection
Capivasertib + Fulvestrant injection is a phase 2 stage product being developed by AstraZeneca for CCCA Assessed by Ki67 Drop Below <2.7% From Baseline. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06607757. Target conditions include CCCA Assessed by Ki67 Drop Below <2.7% From Baseline.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06607757 | Phase 2 | Recruiting |